Reported about 7 hours ago
Merck has paused shipments of its HPV vaccine Gardasil to China due to weak demand, which is likely to negatively affect its 2025 revenue outlook, expected to be between $64.1 billion and $65.6 billion, falling short of analysts' estimates. While the pause began this month amid economic challenges and regulatory issues in China, the company reported a strong fourth-quarter profit primarily driven by sales of its cancer drug Keytruda.
Source: YAHOO